AbCellera Biologics, Inc. (ABCL)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about AbCellera Biologics, Inc. (ABCL)
Go deeper and ask any question about ABCL
Company Performance
Current Price
as of Sep 13, 2024$2.75
P/E Ratio
N/A
Market Cap
$810.33M
Description
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.
Metrics
Overview
- HQVancouver, BC
- SectorHealth Technology
- IndustryBiotechnology
- TickerABCL
- Price$2.75+2.61%
Trading Information
- Market Cap$810.33M
- Float70.13%
- Average Daily Volume (1m)2,340,959
- Average Daily Volume (3m)1,892,659
- EPS-$0.53
Company
- Revenue$33.06M
- Rev Growth (1yr)-27.18%
- Net Income-$36.93M
- Gross Margin-419.42%
- EBITDA Margin-756.75%
- EBITDA-$55.42M
- EV$247.58M
- EV/Revenue7.49
- P/EN/A
- P/S24.48
Documents
SEC Filings
Factset Street Account
Earnings Calls
Factset